CSCharles Spivey

Charles Spivey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles Spivey has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Modulation of PKM activity affects the differentiation of T H 17 cells

    by Scott M. Seki, Kacper Posyniak, Rebecca McCloud, Dorian A. Rosen, Anthony Fernández-Castañeda, Rebecca M. Beiter, Vlad Serbulea, Sarah C. Nanziri, Nikolas Hayes, Charles Spivey, et al.

    Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell function, we assessed their therapeutic activity in a mouse model of T cell–mediated autoimmunity that mimics multiple sclerosis (MS). TH17 cells are believed to orchestrate MS pathology, in part, through the production of two proinflammatory cytokines: interleukin-17 (IL-17) and GM-CSF. We found that both TEPP-46 and DASA-58 suppressed the development of IL-17–producing TH17 cells but increased the generation of those producing GM-CSF. This switch redirected disease pathology from the spinal cord to the brain. In addition, we found that activation of PKM2 interfered with TGF-β1 signaling, which is necessary for the development of TH17 and regulatory T cells. Collectively, our data clarify the therapeutic potential of PKM2 activators in MS-like disease and how these agents alter T cell function.